Viktor Grünwald, MD, University Hospital Essen, Essen, Germany, talks on the implementation of biomarker-driven strategies in renal cell carcinoma (RCC). Prof. Grünwald feels that personalized patient management approaches are the way forward in RCC, but a lack of reliable, high-resolution biomarkers is holding back progress. Lots of research is underway in this field and it is hoped that in the near future, there will be an improved understanding of how to select patients for treatment based on biomarkers. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.